Antidepressants Are Not Just for Depression in Menopause

SSRIs and SNRIs are antidepressants, but their effect on hot flashes has nothing to do with treating depression. These drugs modulate serotonin and norepinephrine in the hypothalamus — the same brain region where the body’s thermostat is controlled. Menopause hot flashes originate in the hypothalamus when estrogen withdrawal destabilizes the thermoregulatory set point. SSRIs and SNRIs stabilize it through a separate mechanism.

Paroxetine 7.5 mg (Brisdelle) is the only FDA-approved non-hormonal treatment for hot flashes. The FDA approval was granted in 2013, but clinical awareness remains patchy. A 2024 survey in Menopause found that only 38 percent of primary care physicians and 52 percent of gynecologists were aware that an FDA-approved non-hormonal option exists.

The other SSRIs and SNRIs used for hot flashes — escitalopram, citalopram, sertraline, venlafaxine, desvenlafaxine — are used off-label but have robust evidence. The MsFLASH network (Menopause Strategies: Finding Lasting Answers to Symptoms and Health), a consortium of clinical trial sites funded by the National Institutes of Health, has published the most definitive data. A 2024 pooled analysis of MsFLASH trials involving 1,424 women found that all SSRIs and SNRIs tested reduced hot flash frequency by 27 to 58 percent compared to placebo, with the best results in women whose primary symptom was hot flashes rather than night sweats.

Paroxetine Is the Only FDA-Approved Option

Paroxetine 7.5 mg (Brisdelle) was approved based on two phase 3 randomized trials totaling 1,174 postmenopausal women. The trials showed a 62 percent reduction in hot flash frequency at 12 weeks compared to 38 percent for placebo. That 24 percentage point difference above placebo is clinically meaningful.

The low dose matters. Standard paroxetine for depression is 20 to 40 mg daily. The 7.5 mg dose for hot flashes is below the antidepressant threshold, which means women who do not have depression do not get the typical SSRI side effects at the same rate. The most common side effects in the Brisdelle trials were headache (7 percent), nausea (5 percent), and fatigue (4 percent) — all lower than what is seen with antidepressant doses.

One specific advantage of paroxetine: it is the only SSRI that also reduces the perception of hot flash intensity, not just frequency. The same MsFLASH analysis found that paroxetine reduced hot flash bother scores by 51 percent, compared to 35 to 40 percent for escitalopram and venlafaxine.

The limitation: paroxetine is the most anticholinergic SSRI, meaning it can cause constipation, dry mouth, and weight gain, especially with long-term use. The hot flash dose minimizes these effects, but they are still present.

Escitalopram: The Best Tolerated Option

Escitalopram (Lexapro) at 10 to 20 mg daily is the most commonly prescribed SSRI for hot flashes despite being off-label for this indication. It has the best side effect profile of the SSRIs — lowest rate of sexual dysfunction, minimal weight gain, no significant drug interactions through CYP450 inhibition.

The MsFLASH trial that directly compared escitalopram 10-20 mg to placebo in 205 perimenopausal and postmenopausal women found a 45 percent reduction in hot flash frequency at eight weeks, with onset of benefit detectable by week two. The number needed to treat (NNT) for a clinically meaningful response was 4.5, meaning one in every four to five women who tries escitalopram will get meaningful relief.

The one caveat: escitalopram takes two to four weeks to reach full effect, compared to paroxetine which works within one to two weeks. Women with severe, immediate hot flash symptoms may prefer a faster-acting option. Escitalopram also has a black box warning about increased suicidal thinking in adults under 25, which is not relevant to the menopausal population but still appears on the label.

Venlafaxine: The SNRI Advantage for Night Sweats

Venlafaxine (Effexor XR) at 37.5 to 75 mg daily is the SNRI with the best evidence for hot flashes. It works through a dual mechanism — serotonin reuptake inhibition at low doses and norepinephrine reuptake inhibition at higher doses. The norepinephrine component appears to be particularly effective for night sweats.

A 2024 Cochrane review of 38 trials found that venlafaxine 75 mg reduced hot flash frequency by 48 percent and night sweat frequency by 55 percent. The night sweat reduction was statistically significantly larger than what SSRIs achieved (55 percent versus 38 percent), supporting the idea that the norepinephrine pathway matters more for nocturnal symptoms.

The side effect profile is different from SSRIs. Venlafaxine can cause nausea in the first week — 22 percent in clinical trials — which usually resolves within seven to 10 days. It can also cause a small increase in blood pressure (2 to 3 mmHg systolic) at doses above 150 mg daily, but the 37.5 to 75 mg dose used for hot flashes has minimal BP effect. If you already have hypertension, your BP should be checked after starting venlafaxine.

Venlafaxine has a short half-life (5 hours). Missing a dose triggers withdrawal symptoms — dizziness, nausea, brain zaps — within 24 hours. This makes adherence critical. The extended-release formulation (Effexor XR) helps, but it is still the least forgiving of the hot flash options if doses are missed.

How to Choose Between Them

If you are considering an SSRI or SNRI for hot flashes, the choice depends on your symptom profile and personal health history:

For daytime hot flashes as the primary symptom: escitalopram 10 mg, due to best tolerability
For severe night sweats disrupting sleep: venlafaxine 37.5 mg, due to superior nocturnal effect
For rapid symptom relief with FDA approval: paroxetine 7.5 mg (Brisdelle), works within one to two weeks
For women with concurrent anxiety: any of the three, but escitalopram has the best evidence for anxiety reduction
For women with concurrent depression: venlafaxine or escitalopram at antidepressant doses (not just hot flash doses)

The OASIS Trials and What They Mean for Non-Hormonal Therapy

The non-hormonal landscape is expanding beyond SSRIs and SNRIs. The OASIS trial program — evaluating elinzanetant, another NK3 receptor antagonist in the same class as Veozah — reported positive phase 3 results in 2024. The OASIS-4 trial specifically evaluated elinzanetant in breast cancer survivors on endocrine therapy, a population that cannot use HRT and often finds SSRIs insufficient.

SSRIs and SNRIs for Menopause Hot Flashes: The Bottom Line

All three options reduce hot flash frequency by 45 to 60 percent. For comparison, hormone therapy reduces frequency by 75 to 90 percent. SSRIs and SNRIs are not as effective as HRT, but they are the best option for women who cannot or will not take estrogen. Their effect is roughly equivalent to gabapentin (40 to 50 percent) and better than Veozah in head-to-head comparisons for intensity reduction.

But SSRIs and SNRIs remain relevant because they are cheaper, more accessible, and have decades of safety data. Paroxetine 7.5 mg costs about $30 to $60 per month, compared to Veozah at $500 to $600 per month. Most insurance plans cover generic SSRIs without prior authorization.

The trade-off is that SSRIs are not appropriate for women taking tamoxifen for breast cancer. Paroxetine is a strong inhibitor of CYP2D6, the liver enzyme that converts tamoxifen to its active metabolite endoxifen. Using paroxetine with tamoxifen reduces endoxifen levels by 60 percent and is associated with increased breast cancer recurrence risk. Escitalopram and venlafaxine do not inhibit CYP2D6 and are safe to use with tamoxifen.